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Abstract
A. Objective: The objective of this selective EBM review is to determine whether or not
intravenous Peramivir 300mg is effective and safe in treating seasonal influenza.
B. Study Design: Review of two randomized controlled trials (RCTs) and one randomized openlabel study, all published in 2010, 2011, and 2014, respectively.
C. Data sources: Two randomized controlled trials and one randomized open- label study were
all researched through the use of PubMed and belonged to peer reviewed journals.
D. Outcome(s) Measured: Primary efficacy endpoint analyzed was time to alleviation of
symptoms measured by influenza symptom severity scale (ISS), a self-assessment four point
scale. The primary safety endpoint measure was incidence of adverse events. The Fischer’s
exact test was used for intergroup comparison of the safety endpoint.
E. Results: When comparing alleviation of symptoms in all three studies, 300mg Peramivir was
as effective as 600mg Peramivir. Both Peramivir groups were superior to the efficacy of placebo.
Analysis of safety, using adverse events, displayed no significant difference between 300mg
Peramivir and comparison groups.
F. Conclusions: After analysis of the three studies in this review, there is significant data to
show 300mg Peramivir is effective and safe in treatment of seasonal influenza.
G. Key Words: Influenza, Peramivir
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1. Introduction
Seasonal influenza is a viral respiratory infection that is highly contagious and in serious
cases can lead to death. This paper evaluates two randomized controlled trials (RCTs) and one
randomized open-label study comparing the efficacy and safety of intravenous Peramivir 300mg
for the treatment of seasonal influenza.
Seasonal influenza is easily transmittable and currently affects over 10% of the
population in the United States. It leads to 200,000 hospitalizations and approximately over
25,000 deaths, per year, in the United States.1 Patients with an underlying chronic respiratory
disease or who are elderly have a significantly increased chance of death if infected by the
seasonal influenza virus, thus making prophylaxis an essential aspect in combating this virus.1
The CDC has conducted data research and found that approximately $10.4 billion is spent
on direct medical expenses for influenza.2 The CDC estimates, that there exists almost an 87
billion dollar economic burden from influenza in the United States. According to the CDC, there
are approximately 31.4 million outpatient visits for flu each year. 2
The presentation and complications of influenza are known. Much research has been
conducted to understand the different strains of influenza that affect the human population. It is
unknown which strains will be affecting the population and when the flu season will occur for a
given year. There are vaccines available yearly to attempt and determine the most likely strains
that the population will be exposed to.
Supportive care is the main treatment for uncomplicated patients which includes
analgesics and rest. Antivirals are chosen for complicated or higher risk patients such as
neuraminidase inhibitors (Oseltamivir and Zanamivir) and M2 inhibitors (Amantadine and
Rimantidine).3
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Most influenza cases are self-limiting thus the medications mentioned help combat the
virus in those at high risk or complicated cases.3 The medications are effective for improvement
of symptoms but do not cure the patient. Neuraminidase inhibitors are able to combat surface
antigens of the virus.3 An issue affecting the treatment of influenza before the consideration of
Peramivir, is the lack of options for route of administration.1 The neuraminidase inhibitors
approved in the United States before Peramivir are Oseltamivir and Zanamivir.3 Oseltamivir and
Zanamivir are only available as oral or inhalation, respectively.3 Peramivir can have the potential
to be an effective choice from the neuraminidase inhibitors due to its unique characteristic of
being intravenously administered.1 If Peramivir can prove to be effective and safe in treating
influenza, it can provide a unique option for management.
2. Objective
The objective of this selective EBM review is to determine whether or not intravenous
Peramivir 300mg is effective and safe in treating seasonal influenza.
3. Methods
For this review, specific criteria were met based on two randomized controlled trials
(RCTs) and one randomized open-label study. The target population utilized was patients ≥14
years of age with influenza. The intervention analyzed was IV Peramivir 300mg which was
further compared to IV Peramivir 600mg and Oseltamivir 75mg. The outcomes measured were
time to alleviation of symptoms and incidence of adverse events.
In the Ison et al1, an open label randomized study, the population consisted of 234
hospitalized patients aged 14 to 92 with seasonal influenza from 59 hospitals in the US, Canada,
Mexico, Australia, and New Zealand. The subjects screened were randomized evenly into two
groups of 117 subjects, one group receiving 300mg Peramivir twice daily and the other 600mg
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Peramivir once daily, respectively. The duration of treatment was for 5 days unless the PCR
showed detectable virus on day 4 of the course. In this case, the treatment was allowed to
continue for 5 more days, for a total of 10 days. 1
The study by Kohno et al4, a double blind randomized controlled trial, included 300
previously healthy adults from 75 hospital centers in Japan. All subjects were aged 20-64 and
recruited within 48 hours of influenza symptom onset. Influenza was confirmed in every subject
by a positive rapid antigen test. The 300 subjects were randomized into three groups: 99 subjects
receiving one single dose of 300mg intravenous Peramivir, 97 subjects receiving single dose of
600mg intravenous Peramivir, and 100 subjects receiving an equivalent single dose of placebo.4
The Kohno et al5 study, a multicenter double blind randomized control trial, incorporated
1,091 patients aged 20 years or older infected with influenza A or B virus. Subjects were from
146 institutions located in Japan, South Korea, and Taiwan. The subjects were divided into three
groups receiving a single dose of intravenous 300mg Peramivir, a single dose of intravenous
600mg Peramivir, and 75mg of oral Oseltamivir twice daily for 5 days, respectively.5
I personally, conducted all of the research for this review via Pubmed NCBI and had
selected the articles by relevance to my clinical question and meeting the criteria of including
patient oriented outcomes (POEMS). The key words used in the searches were “Influenza” and
“Peramivir”. All of the articles were published in English and met the criteria of being published
in peer reviewed journals. All of the studies included in this review were published within the
past 15 years and at least 2 of the studies were RCTs. Studies that included patients less than 14
years of age infected by seasonal influenza were excluded in the review. The statistics reported
or used in the articles were p- values, relative risk increase (RRI), absolute risk increase (ARI),
and numbers needed to harm (NNH).
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Table 1 - Demographics & Characteristics of included studies
Study

Type

#Pts

Age
(yrs)

Inclusion
criteria

Ison1
(2014)

Open
Label
RT

234

≥14

Patients from
59 hospitals
≥14 years of
age with local
influenza
activity in the
US, Canada,
Mexico,
Australia, and
New Zealand

Kohno4
(2010)

Double
blind
RCT

300

2064

Kohno5
(2011)

Double
blind
RCT

1091

≥20

Exclusion criteria

W/
D

Patients who required
54
dialysis, altered
neurological status,
undergoing systemic
chemotherapy or
radiotherapy, recent
hematopoietic stem cell
or organ transplant,
uncontrolled HIV, preexisting chronic infection,
had CF, pre-specified
abnormalities on lab
testing, women who were
pregnant
Patients who
Patients with respiratory
4
were healthy
dysfunction requiring
adults aged
medication, neurologic
20-64 with a
symptoms, active chronic
positive
illness or HIV, on
influenza virus hemodialysis, bacterial
rapid antigen
infection, hx with steroids
test recruited
use of anti-influenza virus
w/i 48hrs of
drugs w/in past 7 days, hx
onset
of hypersensitivity or
serious ADRs to antiinfluenza drugs, pregnant/
breastfeeding
Patients aged
Patients with impaired
8
20 years or
respiratory function,
older with
history of CHF, poorly
influenza A
controlled DM,
or B virus
immunosuppressive
infection in
therapy or AIDS, renal
146 medical
disorder, ischemic heart
institutions in disease or serious
Japan, South
arrhythmia, corrected QT
Korea, and
interval or bradycardia,
Taiwan
required hospitalization,
infection requiring
systemic antibiotics

Interventions
IV Peramivir
300mg bid for
5 days VS.
IV Peramivir
600mg qd for
5 days

IV Peramivir
300mg qd for 1
day VS.
IV Peramivir
600 mg qd for 1
day

IV Peramivir
300mg qd for 1
day VS.
IV Peramivir
600mg qd for 1
day VS.
Oseltamivir
75mg bid for 5
days
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4. Outcomes
The outcomes addressed in this review consisted of patient oriented evidence found in the
studies. In the Ison et al1 study, time to alleviation of symptoms was measured (in hours) using a
four point scale that was filled out twice daily from day 1 to 9 then once daily until day 14. The
scale was utilized by patients to rate their influenza symptoms, specifically cough, sore throat,
nasal congestion, myalgia, headache, feverishness, and fatigue. The study measured adverse
events by a daily checklist represented by a percentage.1
In Kohno et al4 and Kohno et al5, the primary efficacy endpoint analyzed was time to
alleviation of symptoms. This was similarly recorded using a four point scale self-assessment,
influenza symptom severity scale (ISS), rating the seven influenza symptoms mentioned above,
twice daily for day 1 to 9 then once daily until day 14. The scale represented 0 meaning absent;
1, mild; 2, moderate; 3, severe. Alleviation was considered the time (in hours) when all seven
symptoms were rated “0” or “1” for at least 21.5 hours.4 Safety was assessed by the percentage
of adverse events that occurred. They were rated using a graded scale of 1-3 according to the
Division of AIDS table for grading adult and pediatric adverse events. Grades 1-3 represented
mild, moderate, and severe ratings of the events, respectively and intergroup comparison was
made using the Fischer’s exact test.4,5
5. Results
Each study compared 300mg Peramivir differently than the other. The open label study
compared 300mg Peramivir, twice daily, to 600mg Peramivir, once daily alone, the Kohno et al4
RCT, compared both Peramivir groups, single dose, to placebo, and the Kohno et al5 RCT,
compared both Peramivir groups to 75mg Oseltamivir. All studies were conducted in hospital
settings involving subjects with confirmed influenza virus. Ison et al1, included the widest range
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of patients ages (14-92) compared to Kohno et al4 (20-64) and Kohno et al5 (20-80). Efficacy
endpoint results in all studies were represented by continuous data and provided p-values and
confidence intervals. Safety endpoints for all of the studies were able to be converted to
dichotomous data thus relative risk increase (RRI), absolute risk increase (ARI), and numbers
needed to harm (NNH) were calculated for this review for safety.
In Ison et al1, 234 subjects were randomized into two groups, 300mg Peramivir and
600mg Peramivir. Four withdrew before treatment and from the remaining population 127
subjects had confirmed influenza thus leaving the intent to treat population to be 127 subjects.
The study utilized the Kaplan-Meier method in order to measure time to alleviation of symptoms
amongst the subjects. In the 300mg Peramivir group the median time in hours was 135 (95%
CI:89,184) compared to the 600mg Peramivir group of 158 (95% CI:103,306). Safety was
measured by documenting the number of adverse events experienced in the groups. The 300mg
Peramivir group displayed 90 adverse events total (79% of the group) and the 600mg Peramivir
group showed 85 adverse events total (73%). The relative risk increase calculated was 8% and
the absolute risk increase was 6% (Table 2). The numbers needed to harm was calculated to be
17. This means for every 17 patients who took Peramivir 300mg, there was one more incidence
of an adverse event than those who took Peramivir 600mg. There were a total of 22 deaths
recorded in the study, 8 deaths in the 300mg group and 14 deaths in the 600mg group.1
In Kohno et al4, 300 total subjects were randomly allocated to two groups receiving
Peramivir (300mg or 600mg) and one group receiving placebo. Of the total 300 subjects, 4
subjects had withdrawn from the study thus resulting in 296 subjects in the intent to treat
population. Two subjects withdrew after allocation to groups but before treatment, one subject
did not have any symptom assessment data, and one subject lacked laboratory confirmed
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influenza virus. The study utilized Cox proportional-hazards modeling to calculate a hazard ratio
which compares the study groups to placebo. The hazard ratio for time to alleviation of
symptoms for the 99 subjects in the 300mg Peramivir group and the 97 subjects in the 600mg
Peramivir group was 0.681 (95% CI:0.511-0.909, p= 0.0092) and 0.666 (95% CI:0.499-0.890,
p=0.0092), respectively. This is a significant difference showing both groups of Peramivir had
more of an effect on decreasing the time to alleviation of symptoms in comparison to the placebo
group. The efficacy is further assessed and compared when viewing the median time, in hours,
for alleviation of symptoms in each group. The 300mg Peramivir group displayed alleviation
within a median of 59.1 (95% CI:50.9-72.4) compared to 600mg Peramivir and placebo which
resulted in 59.9 (95% CI:54.4-68.1) and 81.8 (95% CI: 68.0-101.5), respectively. P- values were
adjusted and applied to make intergroup comparisons between the Peramivir groups. There was
no significant difference for efficacy between both dosages of Peramivir which is displayed by
an adjusted p- value of 0.0092.4
For assessment of safety the Kohno et al4 study used the Fischer’s exact test to calculate
the p- value for comparing Peramivir with placebo groups. All drugs were generally well
tolerated by all groups and no evidence displayed a significant difference between them. The
incidence of adverse events compared to placebo was calculated to be P= 0.4986 for the 300mg
Peramivir group and P= 1.000 for the 600mg Peramivir group. In terms of number of adverse
events occurring during the study, the Peramivir groups recorded 252 events each while placebo
recorded 257. The most commonly observed adverse events throughout all groups were
gastrointestinal. Diarrhea occurred in 14.1% in the 300mg group, 15.2% in the 600mg group, and
17.0% in the placebo group. There were a total of 10 severe adverse events recorded in all
groups, with QT prolongation being the most common occurrence (two subjects in the 300mg
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group, one subject in 600mg group, and three subjects in the placebo). The 600mg group further
included one subject developing increased blood glucose and one subject with increased blood
creatinine. Placebo displayed one subject with increased blood pressure and one subject with
increased blood glucose.4 The relative risk increase, absolute risk increase and numbers needed
to harm were calculated to be -3.3%, -3%, and -34, respectively (Table 2).
In the Kohno5 study, 1,099 patients were assigned randomly to the three treatment groups
of 300mg Peramivir, 600mg Peramivir, and 75mg Oseltamivir. Two patients lacked post
treatment efficacy data and eight patients dropped out before treatment, leaving 1,091 patients in
the intent to treat population (364 receiving 300mg, 362 receiving 600mg, and 365 receiving
Oseltamivir). The primary efficacy endpoint was calculated using the Cox proportional-hazards
model to compare Peramivir groups to Oseltamivir. Noninferiority of the Peramivir groups to
Oseltamivir was exhibited by hazard ratios of 0.946 (97.5% CI:0.793-1.129) for 300mg
Peramivir group and 0.970 (97.5% CI:0.814-1.157) for the 600mg Peramivir group. Time to
alleviation of symptoms, in hours, for the 300mg Peramivir, 600mg Peramivir, and 75mg
Oseltamivir groups were 78.0 (95% CI:68.4-88.6), 81.0 (95% CI:72.7-91.5), and 81.8 (95%
CI:73.2-91.1), respectively.5
In terms of safety, Kohno et al5 demonstrated incidence of adverse events for the 300mg
Peramivir, 600mg Peramivir, and Oseltamivir groups as 14.0%, 18.1%, and 20.0%, respectively.
This showed the 300mg Peramivir group to be significantly safer in terms of adverse events than
the Oseltamivir group whereas the 600mg Peramivir group was insignificantly less. Adverse
effects of serious stature were most commonly QT prolongation with no significant difference
between the three groups. QT prolongation occurred in 5 subjects receiving 300mg Peramivir, 8
subjects receiving 600mg Peramivir, and 10 subjects receiving Oseltamivir.5 As mentioned in
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table 2, the relative risk increase, absolute risk increase, and numbers needed to harm were -22%,
-15%, -7%, respectively. This negative value for NNH means for every 7 patients who took
Peramivir 300mg , there was one fewer incidence than those who took Peramivir 600mg.
Table 2 - Harm effects
Study
Ison et al1
Kohno et al4
Kohno et al5

CER
73%
90.9%
66%

EER
79%
87.9%
51%

RRI
8%
-3.3%
-22%

ARI
6%
-3%
-15%

NNH
17
-34
-7

6. Discussion
The efficacy and safety of 300mg Peramivir was the scope of this review when analyzing
all three studies. Currently, a single dose of 600mg Peramivir is used for treatment in acute
uncomplicated influenza in adult patients.6 The 600mg Peramivir is directed to be intravenously
infused for 15-30 minutes.6 Thus comparison between the dosages of Peramivir was an important
aspect to address for consideration of 300mg Peramivir.
In Ison et al1, 300mg twice daily, Peramivir displayed less median time to alleviation of
symptoms compared to the 600mg once daily, Peramivir. It can be argued that there is not
enough statistical evidence in this study to determine a superiority between the two groups since
the study did not provide p-values. As far as safety, it seems there is no significance between
both Peramivir groups. Being this was an open label study, there stood no placebo or baseline to
compare the data collected.
In Kohno et al4, both Peramivir groups exhibited statistical evidence of superiority in
efficacy compared to placebo. The Peramivir groups once again did not show a significant
difference between each other. As far as safety, all three groups in the study displayed similar
adverse events.
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Kohno et al5 study had also displayed superiority of the efficacy endpoint in both
Peramivir groups in comparison to Oseltamivir. There was not as much statistical significance in
this study to prove this point compared to the last study mentioned above. The safety endpoint
showed the most differentiation compared to the other studies. The 300mg Peramivir group had a
more significant percentage of subjects without adverse events than the Oseltamivir group.
Limitations were found in the three studies concerning population, exclusion criteria and
comparison groups. All three studies differed in the populations of subjects with Ison et al1
including the United States, Canada, Mexico, Australia, and New Zealand, Kohno et al4
including only Japan, and Kohno et al5 focusing on subjects from Japan, South Korea and
Taiwan. Though Japan was included in two of the three studies this may not provide efficient
overlap of patient population. Population is important in this review also because of the existence
of different influenza strains in each region of the world. Keeping this a constant could show
change in the outcomes and possibly leading to more concise results for specific populations.
In terms of exclusion criteria, potential limitation could have existed when considering
protocol taken. In Ison et al1 the enrollment criteria was more broad thus leading to the
possibility of more severely ill patients involved. In Kohno et al4, the enrollment criteria was
more specific and led to exclusion of high risk patient populations. This could have resulted in
different outcomes for time to alleviation of symptoms due to severely ill patients potentially
taking longer to resolve symptoms. Also, the criteria of Ison et al1 incorporated a population with
a broader variation in strain. A major portion of the subjects suffered from the 2009 H1N1
pandemic strain along with subjects infected with seasonal influenza strains.
7. Conclusion
After analyzing and reviewing the results provided in the three studies, intravenous
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300mg Peramivir is effective and safe for treatment in seasonal influenza. Though, 300mg
Peramivir did not show significant evidence of superior efficacy compared to 600mg groups, the
argument can be made that showing noninferiority is sufficient to allocate further research for the
use of 300mg Peramivir and show effectiveness. Not all studies provided enough statistical
evidence to state 300mg Peramivir as the clear leader amongst all comparison groups. To further
the argument of 300mg Peramivir to be considered as a treatment option, Ison et al1
demonstrated that giving Peramivir at doses of 300mg compared to a single dose of 600mg
Peramivir for multiple days did result in less time to alleviation of symptoms. By displaying
noninferiority to 600mg Peramivir and 75mg Oseltamivir, 300mg Peramivir demonstrated an
ability to be as effective as the treatment options approved at this time. All of the studies showed
the safety endpoint in all groups were not significant. One group did not seem to exhibit an
excess of adverse events over the others.
For future research I would recommend studies to be conducted using populations and
exclusion criteria that are close in detail. I recommend conducting randomized controlled trials
that only include either high risk or previously healthy patients from the United States with
similar influenza strains. In this manner, 300mg Peramivir may be more accurately assessed for
usage.
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